{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:30:06Z","timestamp":1794072606959,"version":"4.8.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118875","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:03:45Z","timestamp":1764882225000},"page":"118875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Immune checkpoint inhibition in renal cell carcinoma: Mechanisms of resistance and emerging therapeutic strategies"],"prefix":"10.1016","volume":"193","author":[{"given":"Ali","family":"Darzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahla","family":"Shokouhfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Farajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Ghafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Deldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Eini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Ghorbani","family":"Vanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-2016","authenticated-orcid":false,"given":"Nastaran","family":"Bahrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol. Et. al."},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cells13010034","article-title":"Emerging immunotherapy approaches for advanced clear cell renal cell carcinoma","volume":"13","author":"Meng","year":"2023","journal-title":"Cells Et. al."},{"issue":"40","key":"10.1016\/j.biopha.2025.118875_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/EDBK_279881","article-title":"Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma","author":"Tenold","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.euf.2020.12.020","article-title":"A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic Syndrome","volume":"8","author":"Huang","year":"2022","journal-title":"Eur. Urol. Focus [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.urology.2020.05.067","article-title":"Gender Differences in Incidence, Diagnosis, Treatments, and Outcomes in Clinically Localized Bladder and Renal Cancer","volume":"151","author":"Gul","year":"2021","journal-title":"Urol. [Internet]"},{"issue":"21","key":"10.1016\/j.biopha.2025.118875_bib7","article-title":"First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?","volume":"13","author":"Vano","year":"2021","journal-title":"Cancers (Basel) [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041071","article-title":"Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice","volume":"11","author":"Lasorsa","year":"2023","journal-title":"Biomedicines"},{"issue":"18","key":"10.1016\/j.biopha.2025.118875_bib9","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1002\/cam4.4190","article-title":"PD-1\/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies","volume":"10","author":"Ding","year":"2021","journal-title":"Cancer Med. Et. al."},{"issue":"13","key":"10.1016\/j.biopha.2025.118875_bib10","article-title":"Decoding ecosystem heterogeneity and transcriptional regulation characteristics of multi-subtype renal cell carcinoma","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s13046-024-03235-0","article-title":"Ferroptosis and the tumor microenvironment","volume":"43","author":"Cui","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/ijms20040840","article-title":"Targeting tumor microenvironment for cancer therapy","volume":"20","author":"Roma-Rodrigues","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.kint.2020.08.028","article-title":"Immune evasion in renal cell carcinoma: Biology, clinical translation, future directions","volume":"99","author":"Wang","year":"2021","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.biopha.2025.118875_bib14","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.biopha.2025.118875_bib15","article-title":"New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis","volume":"13","author":"Larionova","year":"2021","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib16","article-title":"MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer","volume":"10","author":"Yi","year":"2022","journal-title":"Front Cell Dev. Biol. [Internet]"},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib18","first-page":"20","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer [Internet]"},{"issue":"23","key":"10.1016\/j.biopha.2025.118875_bib19","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-24-1690","article-title":"At the Interface of Tumor-Associated Macrophages and Fibroblasts: Immune-Suppressive Networks and Emerging Exploitable Targets","volume":"30","author":"Timperi","year":"2024","journal-title":"Clin. Cancer Res [Internet]"},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","article-title":"Spatial profiling technologies illuminate the tumor microenvironment","volume":"41","author":"Elhanani","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib21","first-page":"1071","article-title":"Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice","volume":"11","author":"Lasorsa","year":"2023","journal-title":"Biomed. [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond Conventional Immune Checkpoint Inhibition: Renal Cell Carcinoma at the Forefront of Solid Tumor Immunology","volume":"18","author":"Braun","year":"2021","journal-title":"Nat. Rev. Clin. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib23","first-page":"1","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-) 1\/PD-ligand (L) 1 in urological cancers: the \u201call-around warrior\u201d in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2025.118875_bib26","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.kint.2020.08.028","article-title":"Immune evasion in renal cell carcinoma: biology, clinical translation, future directions","volume":"99","author":"Wang","year":"2021","journal-title":"Kidney Int [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118875_bib29","doi-asserted-by":"crossref","first-page":"1146738","DOI":"10.3389\/fimmu.2023.1146738","article-title":"The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma","volume":"14","author":"Su","year":"2023","journal-title":"Front Immunol. Et. al."},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clgc.2023.01.005","article-title":"The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis","volume":"21","author":"Monteiro","year":"2023","journal-title":"Clin. Genitourin. Cancer [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib31","article-title":"Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer","volume":"9","author":"Iranzo","year":"2022","journal-title":"Front Med (Lausanne) [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib32","article-title":"Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice","volume":"11","author":"Lasorsa","year":"2023","journal-title":"Biomed. [Internet]"},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol. Et. al."},{"issue":"11","key":"10.1016\/j.biopha.2025.118875_bib34","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer Et. al."},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol. Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib36","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J. Immunother. Cancer Et. al"},{"issue":"11","key":"10.1016\/j.biopha.2025.118875_bib37","article-title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","volume":"10","author":"Choueiri","year":"2022","journal-title":"J. Immunother. Cancer Et. al"},{"issue":"43","key":"10.1016\/j.biopha.2025.118875_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_389650","article-title":"Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?","author":"Fahey","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib39","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1038\/s41467-021-26415-4","article-title":"Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma","volume":"12","author":"Campbell","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2025.118875_bib40","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma ([translate: TITAN-RCC]): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol. Et. al"},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib41","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J. Immunother. Cancer Et. al"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jjco\/hyaa229","article-title":"Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma","volume":"51","author":"Tachibana","year":"2021","journal-title":"Jpn J. Clin. Oncol. Et. al."},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib43","article-title":"Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial","volume":"13","author":"Luke","year":"2025","journal-title":"J. Immunother. Cancer Et. al"},{"issue":"7","key":"10.1016\/j.biopha.2025.118875_bib44","article-title":"Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214","volume":"12","author":"Mantia","year":"2024","journal-title":"J. Immunother. Cancer Et. al"},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bju.16190","article-title":"A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma","volume":"133","author":"Conduit","year":"2024","journal-title":"BJU Int. Et. al"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41467-024-55642-8","article-title":"Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial","volume":"16","author":"Msaouel","year":"2025","journal-title":"Nat. Commun. Et. al."},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib47","article-title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial","volume":"9","author":"Choueiri","year":"2024","journal-title":"ESMO Open. Et. al."},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib48","article-title":"Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab","volume":"22","author":"Ornstein","year":"2024","journal-title":"Clin. Genitourin. Cancer Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib49","article-title":"A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC","volume":"30","author":"Hahn","year":"2025","journal-title":"Oncol. Et. al"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib50","article-title":"Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab\/ipilimumab in advanced clear cell renal cell carcinoma ([translate: HCRN GU16-260-Cohort A","volume":"12","author":"Atkins","year":"2024","journal-title":"J. Immunother. Cancer Et. al"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib51","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.euo.2023.09.009","article-title":"Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the ([translate: GETUG-AFU-26 NIVOREN Phase 2]) Trial","volume":"7","author":"Billon","year":"2024","journal-title":"Eur. Urol. Oncol. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib52","article-title":"A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma","volume":"14","author":"Alhalabi","year":"2025","journal-title":"Cancer Med. Et. al"},{"issue":"14","key":"10.1016\/j.biopha.2025.118875_bib53","article-title":"Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma ([translate: CheckMate 742]) and renal cell carcinoma ([translate: CheckMate 800])","volume":"131","author":"Menzies","year":"2025","journal-title":"Cancer Et. al"},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol. [Internet]"},{"issue":"10189","key":"10.1016\/j.biopha.2025.118875_bib55","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet [Internet]"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib56","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.euo.2024.06.006","article-title":"Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of ([translate: IMmotion010])","volume":"7","author":"Karam","year":"2024","journal-title":"Eur. Urol. Oncol. Et. al."},{"issue":"33","key":"10.1016\/j.biopha.2025.118875_bib57","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study","volume":"39","author":"Pal","year":"2021","journal-title":"J. Clin. Oncol. Et. al."},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib58","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.3390\/curroncol28060455","article-title":"Phase Ib Study of Atezolizumab Plus Interferon-\u03b1 with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors","volume":"28","author":"Blank","year":"2021","journal-title":"Curr. Oncol. Et. al"},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib59","article-title":"Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study","volume":"8","author":"Sherman","year":"2023","journal-title":"ESMO Open. Et. al"},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib60","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.euo.2023.10.017","article-title":"A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer","volume":"7","author":"Kotecha","year":"2024","journal-title":"Eur. Urol. Oncol. Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib62","article-title":"Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101","volume":"7","author":"Tomita","year":"2022","journal-title":"ESMO Open. Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oncolo\/oyad231","article-title":"Patient-Reported Outcomes in ([translate: KEYNOTE-564]): Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncol. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib64","first-page":"333","article-title":"Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the ([translate: JAVELIN Renal 100 Phase Ib","volume":"28","author":"Larkin","year":"2023","journal-title":"Trial Oncol. Et. al."},{"issue":"11","key":"10.1016\/j.biopha.2025.118875_bib65","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann. Oncol. Et. al."},{"issue":"10397","key":"10.1016\/j.biopha.2025.118875_bib66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment ([translate: CONTACT-03]): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib67","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann. Oncol. Et. al."},{"issue":"7","key":"10.1016\/j.biopha.2025.118875_bib68","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma ([translate: Study 111\/KEYNOTE-146]): a phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol. Et. al"},{"issue":"10460","key":"10.1016\/j.biopha.2025.118875_bib69","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet Et. al."},{"key":"10.1016\/j.biopha.2025.118875_bib70","first-page":"129","article-title":"A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial ([translate: Meet-Uro trial 03])","volume":"109","author":"Procopio","year":"2023"},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib71","article-title":"Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study","volume":"30","author":"Zugman","year":"2025","journal-title":"Oncol. Et. al"},{"issue":"22","key":"10.1016\/j.biopha.2025.118875_bib72","article-title":"Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma","volume":"5","author":"Wood","year":"2020","journal-title":"JCI Insight Et. al."},{"issue":"15","key":"10.1016\/j.biopha.2025.118875_bib73","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res. Et. al."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib74","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10147-021-02014-7","article-title":"Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label ([translate: KEYNOTE-426]) study","volume":"27","author":"Tamada","year":"2022","journal-title":"Int J. Clin. Oncol. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib75","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jjco\/hyae182","article-title":"First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 ([translate: KEYNOTE-426]) in Eastern Asia","volume":"55","author":"Chung","year":"2025","journal-title":"Jpn J. Clin. Oncol. Et. al."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib76","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann. Oncol. Et. al."},{"key":"10.1016\/j.biopha.2025.118875_bib77","first-page":"8","article-title":"Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the ([translate: JAVELIN Renal 101 Phase 3]) Trial","volume":"85","author":"Grimm","year":"2024"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/oncolo\/oyae003","article-title":"The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214","volume":"29","author":"Cella","year":"2024","journal-title":"Oncol. Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib79","article-title":"Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy","volume":"7","author":"Grande","year":"2022","journal-title":"ESMO Open. Et. al."},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib80","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.eururo.2023.09.004","volume":"84","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur. Urol. Et. al."},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib81","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2021.01.003","article-title":"Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in ([translate: IMmotion150]): A Randomized Phase 2 Clinical Trial","volume":"79","author":"Powles","year":"2021","journal-title":"Eur. Urol. Et. al"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib82","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.3390\/curroncol28060455","article-title":"Phase Ib Study of Atezolizumab Plus Interferon-\u03b1 with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors","volume":"28","author":"Blank","year":"2021","journal-title":"Curr. Oncol. Et. al"},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib83","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clgc.2021.04.007","article-title":"A Phase I\/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma","volume":"19","author":"Chowdhury","year":"2021","journal-title":"Clin. Genitourin. Cancer Et. al."},{"issue":"11","key":"10.1016\/j.biopha.2025.118875_bib84","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.21037\/tcr-20-1975","article-title":"The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis","volume":"9","author":"He","year":"2020","journal-title":"Transl. Cancer Res [Internet]"},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib85","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open [Internet]"},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol. [Internet]"},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib87","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO Open [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib88","article-title":"Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"165","author":"Inno","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol. [Internet"},{"issue":"25","key":"10.1016\/j.biopha.2025.118875_bib89","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1111\/1759-7714.15063","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis","volume":"14","author":"Feng","year":"2023","journal-title":"Thorac. Cancer [Internet]"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib90","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J. Leukoc. Biol. [Internet]"},{"issue":"9","key":"10.1016\/j.biopha.2025.118875_bib91","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib92","doi-asserted-by":"crossref","unstructured":"Powles T., Albiges L., Bex A., Comperat E., Gr\u00fcnwald V., Kanesvaran R., et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Annals of Oncology [Internet]. 2024 Aug 1 [cited 2025 Oct 23];35(8):692\u2013706. Available from: https:\/\/www.annalsofoncology.org\/action\/showFullText?pii=S0923753424006768.","DOI":"10.1016\/j.annonc.2024.05.537"},{"issue":"18","key":"10.1016\/j.biopha.2025.118875_bib93","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer Et. al."},{"key":"10.1016\/j.biopha.2025.118875_bib94","article-title":"Salvage lenvatinib\/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma","volume":"13","author":"Kwok","year":"2023","journal-title":"Front Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib95","doi-asserted-by":"crossref","first-page":"1097911","DOI":"10.3389\/fonc.2023.1097911","article-title":"Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study","volume":"13","author":"Deng","year":"2023","journal-title":"Front Oncol. Et. al."},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib96","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/onco.13770","article-title":"Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies","volume":"26","author":"Wiele","year":"2021","journal-title":"Oncol. Et. al"},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030557","article-title":"Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors\/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival","volume":"16","author":"Ossato","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib98","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","article-title":"Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience","volume":"18","author":"Iyer","year":"2020","journal-title":"Clin. Genitourin. Cancer Et. al."},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib99","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur. Urol. Et. al."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyy179","article-title":"Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset","volume":"49","author":"Ohe","year":"2019","journal-title":"Jpn J. Clin. Oncol. Et. al."},{"issue":"7","key":"10.1016\/j.biopha.2025.118875_bib101","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jjco\/hyx049","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study","volume":"47","author":"Tomita","year":"2017","journal-title":"Jpn J. Clin. Oncol. Et. al."},{"key":"10.1016\/j.biopha.2025.118875_bib102","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/TCRM.S126910","article-title":"Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma","volume":"13","author":"Leonetti","year":"2017","journal-title":"Ther. Clin. Risk Manag"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib103","article-title":"Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial","volume":"12","author":"Huang","year":"2024","journal-title":"J. Immunother. Cancer Et. al"},{"issue":"8","key":"10.1016\/j.biopha.2025.118875_bib104","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy ([translate: PROSPER ECOG-ACRIN EA8143]): an open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol. Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib105","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oncolo\/oyad231","article-title":"Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncol. [Internet]"},{"issue":"3","key":"10.1016\/j.biopha.2025.118875_bib106","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.eururo.2024.05.012","article-title":"Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled ([translate: SWOG S0931 (EVEREST)","volume":"86","author":"PNJr","year":"2024","journal-title":"Trial Eur. Urol. Et. al."},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib107","first-page":"5684","article-title":"Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma","volume":"27","author":"Shen","year":"2023","journal-title":"Eur. Rev. Med Pharm. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib108","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.24.00773","article-title":"Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial","volume":"43","author":"Motzer","year":"2025","journal-title":"J. Clin. Oncol. Et. al."},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib109","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2024.02.014","article-title":"Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study","volume":"86","author":"Iacovelli","year":"2024","journal-title":"Eur. Urol. Et. al."},{"issue":"10379","key":"10.1016\/j.biopha.2025.118875_bib110","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy ([translate: CheckMate 914]): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet Et. al."},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib111","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","article-title":"Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy","volume":"81","author":"Carlo","year":"2022","journal-title":"Eur. Urol. Et. al."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib112","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat. Commun. Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib113","article-title":"Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis of Individual Patient Data","volume":"11","author":"Makrakis","year":"2025","journal-title":"Eur. Urol. Focus [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib114","article-title":"Perioperative systemic treatments in renal cell carcinoma","volume":"14","author":"Goswamy","year":"2024","journal-title":"Front Oncol. [Internet]"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib115","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","article-title":"Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy","volume":"81","author":"Carlo","year":"2022","journal-title":"Eur. Urol. [Internet]"},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial","volume":"5","author":"Bex","year":"2018","journal-title":"JAMA Oncol. [Internet]"},{"issue":"10","key":"10.1016\/j.biopha.2025.118875_bib117","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00262-022-03166-9","article-title":"Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood","volume":"71","author":"Keber","year":"2022","journal-title":"Cancer Immunol. Immunother. [Internet]"},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib118","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s11255-021-02841-7","article-title":"Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer","volume":"53","author":"M\u00f6ller","year":"2021","journal-title":"Int Urol. Nephrol. [Internet]"},{"issue":"7\u20138","key":"10.1016\/j.biopha.2025.118875_bib119","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1159\/000506296","article-title":"Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"104","author":"Shen","year":"2020","journal-title":"Urol. Int [Internet]"},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib120","article-title":"Soluble PD-L1 as an early marker of progressive disease on nivolumab","volume":"10","author":"Mahoney","year":"2022","journal-title":"J. Immunother. Cancer [Internet]"},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib121","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/life15040626","article-title":"Soluble PD-L1: From Immune Evasion to Cancer Therapy","volume":"15","author":"Dragu","year":"2025","journal-title":"Life [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib122","doi-asserted-by":"crossref","unstructured":"Choueiri T.K., Fay A.P., Gray K.P., Callea M., Ho T.H., Albiges L., et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology [Internet]. 2014 Nov 1 [cited 2025 Nov 27];25(11):2178\u201384. Available from: \u3008https:\/\/www.annalsofoncology.org\/action\/showFullText?pii=S0923753419367870\u3009.","DOI":"10.1093\/annonc\/mdu445"},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib123","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.7150\/jca.35738","article-title":"Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma","volume":"11","author":"Walter","year":"2020","journal-title":"J. Cancer [Internet]"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib124","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21037\/atm.2020.02.81","article-title":"Tumor mutational burden and immune signatures interplay in renal cell carcinoma","volume":"8","author":"Yakirevich","year":"2020","journal-title":"Ann. Transl. Med"},{"issue":"9","key":"10.1016\/j.biopha.2025.118875_bib125","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.21037\/tcr-21-561","article-title":"A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets","volume":"10","author":"Cai","year":"2021","journal-title":"Transl. Cancer Res"},{"issue":"15","key":"10.1016\/j.biopha.2025.118875_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34877","article-title":"Predicting CTLA4 expression and prognosis in clear cell renal cell carcinoma using a pathomics signature of histopathological images and machine learning","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib127","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.biopha.2025.118875_bib128","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med. Et. al"},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib129","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med. Et. al"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med. Et. al."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib131","doi-asserted-by":"crossref","first-page":"314","DOI":"10.20517\/cdr.2023.09","article-title":"Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma","volume":"6","author":"Chatwal","year":"2023","journal-title":"Cancer Drug Resist."},{"issue":"4","key":"10.1016\/j.biopha.2025.118875_bib132","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib133","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118875_bib134","article-title":"Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer","volume":"80","author":"Hargadon","year":"2023","journal-title":"Cell Mol. Life Sci. [Internet]"},{"issue":"7","key":"10.1016\/j.biopha.2025.118875_bib135","article-title":"Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway","volume":"24","author":"Massa","year":"2023","journal-title":"Int J. Mol. Sci. [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib136","article-title":"Mechanisms of Cancer Resistance to Immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol. [Internet]"},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib137","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s10147-019-01611-x","article-title":"Immune-resistant mechanisms in cancer immunotherapy","volume":"25","author":"Kawakami","year":"2020","journal-title":"Int J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib138","doi-asserted-by":"crossref","unstructured":"Saleh R., Elkord E. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Semin Cancer Biol [Internet]. 2020 Oct 1 [cited 2025 Nov 27];65:13\u201327. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/31362073\/\u3009.","DOI":"10.1016\/j.semcancer.2019.07.017"},{"key":"10.1016\/j.biopha.2025.118875_bib139","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2025.118875_bib140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","article-title":"Acquired resistance in cancer: towards targeted therapeutic strategies","volume":"25","author":"Soragni","year":"2025","journal-title":"Nat. Rev. Cancer [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib141","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","article-title":"The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma","volume":"11","author":"Zhang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"9","key":"10.1016\/j.biopha.2025.118875_bib142","first-page":"1","article-title":"Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib143","article-title":"Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol. [Internet]"},{"issue":"16","key":"10.1016\/j.biopha.2025.118875_bib144","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade","volume":"82","author":"Jenkins","year":"2022","journal-title":"Cancer Res [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib145","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.3390\/cancers14143321","article-title":"Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib146","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu Rev. Immunol. [Internet]"},{"issue":"7","key":"10.1016\/j.biopha.2025.118875_bib147","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1007\/s12094-025-03848-7","article-title":"Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors","volume":"27","author":"Yal\u00e7\u0131ner","year":"2025","journal-title":"Clin. Transl. Oncol. [Internet]"},{"issue":"18","key":"10.1016\/j.biopha.2025.118875_bib148","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2217\/imt-2022-0133","article-title":"Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis","volume":"14","author":"Tian","year":"2022","journal-title":"Immunother. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib149","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cpt.2023.08.001","article-title":"Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors","volume":"2","author":"Hou","year":"2024","journal-title":"Cancer Pathog. Ther. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-024-01541-w","article-title":"Critical role of the gut microbiota in immune responses and cancer immunotherapy","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib151","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","article-title":"Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies","volume":"15","author":"Lu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118875_bib152","article-title":"Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr. Oncol. Rep. [Internet]"},{"issue":"10","key":"10.1016\/j.biopha.2025.118875_bib153","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jamaoncol.2020.2169","article-title":"Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma","volume":"6","author":"Ravi","year":"2020","journal-title":"JAMA Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib154","article-title":"Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol. [Internet]"},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib155","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.3390\/cancers15123172","article-title":"Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions","volume":"15","author":"Sammarco","year":"2023","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1270828","article-title":"Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib157","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.3390\/ijms26125577","article-title":"Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma ([translate: ccRCC","volume":"26","author":"Rysz","year":"2025","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib158","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib159","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol. [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib160","article-title":"Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy","volume":"120","author":"Liu","year":"2019","journal-title":"Biomed. Pharmacother. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib161","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/gastro\/goz065","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy","volume":"8","author":"Rajha","year":"2019","journal-title":"Gastroenterol. Rep. (Oxf. ) [Internet]"},{"issue":"16","key":"10.1016\/j.biopha.2025.118875_bib162","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/cancers17162651","article-title":"Endocrine Adverse Events Induced by Cancer Treatments: The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography","volume":"17","author":"Giovanella","year":"2025","journal-title":"Cancers (Basel) [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib163","doi-asserted-by":"crossref","unstructured":"Karayama M. Immune checkpoint inhibitor-related pneumonitis: From guidelines to the front lines. Respir Investig [Internet]. 2025 Sep 1 [cited 2025 Oct 23];63(5):1002\u201311. Available from: \u3008https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2212534525001248\u3009.","DOI":"10.1016\/j.resinv.2025.07.023"},{"key":"10.1016\/j.biopha.2025.118875_bib164","article-title":"Central nervous system complications of immune checkpoint inhibitors: A comprehensive review","volume":"206","author":"Lopes","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol. [Internet"},{"key":"10.1016\/j.biopha.2025.118875_bib165","doi-asserted-by":"crossref","unstructured":"He Y., Yu H., Dai S., He M., Ma L., Xu Z., et al. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology. Genes Dis [Internet]. 2024 Mar 1 [cited 2025 Oct 23];11(2):807\u201318. Available from: \u3008https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352304223000478\u3009.","DOI":"10.1016\/j.gendis.2023.01.024"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib166","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis Oncol. [Internet"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib167","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10147-019-01542-7","article-title":"Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer","volume":"25","author":"Fujiwara","year":"2020","journal-title":"Int J. Clin. Oncol. [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib168","article-title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat. Rev. Et. al."},{"key":"10.1016\/j.biopha.2025.118875_bib169","article-title":"Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review","volume":"103","author":"McGregor","year":"2022","journal-title":"Cancer Treat. Rev. [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib170","doi-asserted-by":"crossref","unstructured":"Motzer R.J., Tykodi S.S., Escudier B., Oudard S., Hammers H.J., McDermott D.F.. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with> 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). In: et al. American Society of Clinical Oncology; 2020.","DOI":"10.1200\/JCO.2020.38.6_suppl.617"},{"key":"10.1016\/j.biopha.2025.118875_bib171","article-title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","volume":"199","author":"Brahmer","year":"2024","journal-title":"Eur. J. Cancer [Internet]"},{"issue":"36","key":"10.1016\/j.biopha.2025.118875_bib172","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.2217\/fon-2020-0586","article-title":"Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma","volume":"16","author":"Soleimani","year":"2020","journal-title":"Future Oncol. [Internet]"},{"issue":"12","key":"10.1016\/j.biopha.2025.118875_bib173","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma ([translate: KEYNOTE-426]): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol. Et. al."},{"issue":"11","key":"10.1016\/j.biopha.2025.118875_bib174","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-19-2838","article-title":"Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma","volume":"26","author":"Atkins","year":"2020","journal-title":"Clin. Cancer Res [Internet]"},{"issue":"9","key":"10.1016\/j.biopha.2025.118875_bib175","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med. Et. al"},{"issue":"7","key":"10.1016\/j.biopha.2025.118875_bib176","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma ([translate: CheckMate 9ER]): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol. Et. al."},{"issue":"8","key":"10.1016\/j.biopha.2025.118875_bib177","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1078-0432.CCR-21-3149","article-title":"Exposure\u2013Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma","volume":"28","author":"Hamuro","year":"2022","journal-title":"Clin. Cancer Res. Et. al"},{"key":"10.1016\/j.biopha.2025.118875_bib178","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2022.09.020","article-title":"Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial","volume":"177","author":"Apolo","year":"2022","journal-title":"Eur. J. Cancer Et. al."},{"issue":"14","key":"10.1016\/j.biopha.2025.118875_bib179","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med. [Internet]"},{"issue":"19","key":"10.1016\/j.biopha.2025.118875_bib180","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N. Engl. J. Med [Internet]"},{"key":"10.1016\/j.biopha.2025.118875_bib181","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251371479","article-title":"Analysis of the Efficacy and Safety of Cabozantinib Monotherapy Versus Its Combination with Atezolizumab in Cancer Patients: A Systematic Review and Meta-Analysis","author":"Pakdaman","year":"2025","journal-title":"Cancer Control [Internet]"},{"issue":"8","key":"10.1016\/j.biopha.2025.118875_bib182","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","article-title":"Immune checkpoint inhibitor combinations\u2014current and emerging strategies","volume":"128","author":"Walsh","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib183","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","article-title":"Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective","volume":"25","author":"Sherafat","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118875_bib184","article-title":"Harnessing helminth-driven immunoregulation in the search for novel therapeutic modalities","volume":"16","author":"Ryan","year":"2020","journal-title":"PLoS Pathog. [Internet]"},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-022-00378-0","article-title":"The role of biomarkers in personalized immunotherapy","volume":"10","author":"Sankar","year":"2022","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib186","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.biopha.2025.118875_bib187","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions","volume":"26","author":"Hsu","year":"2025","journal-title":"Clin. Exp. Med [Internet]"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib188","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.euf.2024.12.006","article-title":"Clinical Applications of Microbiome in Renal Cell Carcinoma","volume":"10","author":"Elyas","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.biopha.2025.118875_bib189","article-title":"Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy","author":"Hu","year":"2025","journal-title":"Chin. Med J. (Engl. ) [Internet]"},{"issue":"6529","key":"10.1016\/j.biopha.2025.118875_bib190","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Sci. [Internet]"},{"issue":"6","key":"10.1016\/j.biopha.2025.118875_bib191","article-title":"Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care","volume":"1878","author":"Ciernikova","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) Reviews Cancer [Internet]"}],"updated-by":[{"DOI":"10.1016\/j.biopha.2026.118994","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000}},{"DOI":"10.1016\/j.biopha.2026.118994","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:10:54Z","timestamp":1777014654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":191,"alternative-id":["S0753332225010698"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118875","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibition in renal cell carcinoma: Mechanisms of resistance and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118875"}}